Trolamine salicylate

Identification

Name
Trolamine salicylate
Accession Number
DB11079
Type
Small Molecule
Groups
Approved
Description

Trolamine salicylate is an organic compound or a salt formed between triethanolamine and salicylic acid. Triethanolamine neutralizes the acidity of the salicylic acid. It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises. Unlike other topical analgesics, trolamine salicylate has no distinct odor which improves patient acceptability [2]. It also displays low systemic absorption upon dermal or topical administration [3] and has low skin irritant properties [4]. As with other salicylates, trolamine salicylate is an inhibitor of cyclo-oxygenase (COX) enzymes with no reported selectivity towards a specific enzyme isoform. Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains.

Structure
Thumb
Synonyms
Not Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actiflex Pain Relief RubCream10 %TopicalPendopharm Division Of De Pharmascience Inc2003-01-202011-09-30Canada
Alcis Daily Relief Pain ReliefCream10 g/100mLTopicalAlcis Topical, Inc.2009-03-09Not applicableUs
Alcis Topical Pain Relief CreamCream10 %TopicalAlcis Health Inc.Not applicableNot applicableCanada
AnalgesicCream10 g/100gTopicalMeijer Distribution1990-04-152017-11-22Us
Analgesic CreamCream15 %TopicalPharmascience Inc2013-10-08Not applicableCanada
Analgesic Cream Extra Strength OdorlessCream15 %TopicalPharmascience Inc1999-10-09Not applicableCanada
Analgesic Creme RubCream100 mg/gTopicalMajor2014-05-10Not applicableUs
Antiphlogistine Rub A-535 No Odour Fmla OntOintment13.3 %TopicalCarter Products, Division Of Carter Wallace Ns Inc.1993-12-311997-08-14Canada
ArthricreamCream10 g/100gTopicalWalmart Stores2009-04-25Not applicableUs
ArthricreamCream10 g/100gTopicalKroger1992-02-04Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Arthritis Extra Strength Roll-ON LotionTrolamine salicylate (10 %) + Capsaicin (0.035 %) + Menthol (1.25 %)LotionTopicalChurch & Dwight Company, Inc.2008-09-15Not applicableCanada
Arthur Itis CreamTrolamine salicylate (10 %) + Capsaicin (0.025 %)CreamTopicalNabtech Pharma Inc.1997-09-262005-09-20Canada
Ease Pain Away Analgesic LotionTrolamine salicylate (10 %) + Menthol (1.25 %)LotionTopicalRmc Group Inc.1994-12-311999-11-23Canada
ELF Flawless Finish Foundation SPF 15 Oil FreeTrolamine salicylate (2 g/100g) + Titanium dioxide (5.5 g/100g)CreamTopicalJ. A. Cosmetics U.S. INC2011-10-03Not applicableUs
Myoflex Extra Strength IceTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care2003-10-302007-08-02Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalSterling Winthrop Inc.1994-12-311996-09-10Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care1996-09-101997-08-01Canada
Myoflex Ice Plus - CrmTrolamine salicylate (15 %) + Menthol (3 %)CreamTopicalBayer Inc Consumer Care1994-12-302004-06-28Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Permavan External PatchTrolamine salicylate (10 g/100g) + Dextromethorphan hydrobromide (4 g/100g) + Lidocaine (4 g/100g)PatchTopicalHome Aide Diganostics, Inc.2015-03-09Not applicableUs
Categories
UNII
H8O4040BHD
CAS number
2174-16-5
Weight
Average: 287.312
Monoisotopic: 287.1368874
Chemical Formula
C13H21NO6
InChI Key
UEVAMYPIMMOEFW-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2
IUPAC Name
2-[bis(2-hydroxyethyl)amino]ethan-1-ol; 2-hydroxybenzoic acid
SMILES
OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Indicated for the temporary relief of aches, and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments [6].

Structured Indications
Not Available
Pharmacodynamics

Trolamine salicylate is a salicylate that inhibits cyclo-oxygenase (COX) enzymes responsible for generating pro-inflammatory factors such as to induce pain and inflammation. It is thought to mediate its analgesic effect through inhibition of COX-2 enzyme, which is an induced enzyme responsible for inflammatory responses and pain in muscle and joint disorders. By inhibiting fatty acid COX enzyme, trolamine salicylate inhibits the production of prostaglandins and thromboxanes in inflammatory cells involved in generating pain and inflammation [5]. It thereby works to temporarily reduce mild to moderate pain. In subjects with muscle soreness from exercise, administration of topical trolamine salicylate was associated with reduced duration and severity of muscule soreness compared to placebo [2]. In subjects with osteoarthritis in hands, trolamine salicylate cream was shown to be effective in achieving temporary relief of minor pain and stiffness [1].

Mechanism of action

Inflammation and tissue damage in different conditions including arthritis, bursitis, joint disorder, bruises, and strains or sprains of muscle origin, induce mild to moderate pain and are associated with increase prostaglandin synthesis [5]. This is thought to be a result of COX-2 enzyme induction. COX-2 is induced in inflammatory cells in case of cell injury, infection or activation from inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-α. Upon activation, COX-2 produces prostanoid mediators of inflammation such as prostaglandins and thromboxanes [5]. Trolamine salicylate mediates its analgesic effect by inhibiting the production of inflammatory mediators that sensitize nociceptive nerve endings and generate pain [5].

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Following topical administration of 10% trolamine salicylate in healthy volunteers, salicylic acid could not be detected in serum indicating low systemic absorption [3].

Volume of distribution

Topical administration of 1 gram of 10% trolamine salicylate in abdominal rat skin resulted in an approximate extravascular volume of distribution (V/F) of 24.0 mL [4].

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Following topical administration of 10% trolamine salicylate in healthy volunteers, urinary recovery of total salicylate during the first 24 hours was 6.9 mg (p < 0.05), which is 1.4% of total dose [3].

Half life
Not Available
Clearance
Not Available
Toxicity

It is hazardous in case of ingestion [MSDS]. The carcinogenicity, mutagenicity and effects on reproductive fertility of trolamine salicylate have not been reported.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Trolamine salicylate.Approved
AcarboseTrolamine salicylate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolTrolamine salicylate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trolamine salicylate.Approved, Vet Approved
AlbiglutideTrolamine salicylate may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aldosterone.Experimental, Investigational
AlogliptinTrolamine salicylate may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Trolamine salicylate.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Trolamine salicylate.Approved
Ammonium chlorideThe serum concentration of Trolamine salicylate can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Trolamine salicylate.Approved
AncrodTrolamine salicylate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trolamine salicylate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anistreplase.Approved
Antithrombin III humanTrolamine salicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTrolamine salicylate may increase the anticoagulant activities of Apixaban.Approved
ArdeparinTrolamine salicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Trolamine salicylate.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trolamine salicylate.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Trolamine salicylate.Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Batroxobin.Experimental
BecaplerminTrolamine salicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Trolamine salicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Betamethasone.Approved, Vet Approved
BivalirudinTrolamine salicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Brinzolamide.Approved
BromocriptineTrolamine salicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Trolamine salicylate.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Trolamine salicylate.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Trolamine salicylate.Investigational
CanagliflozinTrolamine salicylate may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Trolamine salicylate.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Trolamine salicylate.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Caplacizumab.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Trolamine salicylate.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Trolamine salicylate.Experimental, Investigational
CertoparinTrolamine salicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamideTrolamine salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CiclesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Trolamine salicylate.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Trolamine salicylate.Approved, Investigational
Citric AcidTrolamine salicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Trolamine salicylate.Experimental
ClorindioneTrolamine salicylate may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortisone acetate.Approved, Investigational
Dabigatran etexilateTrolamine salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTrolamine salicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTrolamine salicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinTrolamine salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanTrolamine salicylate may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Trolamine salicylate.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Trolamine salicylate.Experimental
DersalazineDersalazine may increase the anticoagulant activities of Trolamine salicylate.Investigational
DesirudinTrolamine salicylate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexketoprofen.Approved, Investigational
DextranTrolamine salicylate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Trolamine salicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Trolamine salicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Trolamine salicylate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diclofenamide.Approved, Investigational
DicoumarolTrolamine salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational
DiphenadioneTrolamine salicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Trolamine salicylate.Approved
DisopyramideTrolamine salicylate may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideTrolamine salicylate may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
Edetic AcidTrolamine salicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTrolamine salicylate may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinTrolamine salicylate may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Trolamine salicylate.Approved
EnoxaparinTrolamine salicylate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Trolamine salicylate.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Trolamine salicylate.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Trolamine salicylate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Trolamine salicylate.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Trolamine salicylate.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateTrolamine salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideTrolamine salicylate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Ferulic acidTrolamine salicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fludrocortisone.Approved, Investigational
FluindioneTrolamine salicylate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flurandrenolide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone propionate.Approved
FondaparinuxTrolamine salicylate may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTrolamine salicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Trolamine salicylate.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
GabexateTrolamine salicylate may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational, Nutraceutical
GliclazideTrolamine salicylate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTrolamine salicylate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTrolamine salicylate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideTrolamine salicylate may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Trolamine salicylate.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with HE3286.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Trolamine salicylate.Experimental
HeparinTrolamine salicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Trolamine salicylate.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Trolamine salicylate.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Trolamine salicylate.Approved, Investigational, Nutraceutical
IdraparinuxTrolamine salicylate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Trolamine salicylate.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Trolamine salicylate.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Trolamine salicylate.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Trolamine salicylate.Investigational
Insulin AspartTrolamine salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTrolamine salicylate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTrolamine salicylate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTrolamine salicylate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTrolamine salicylate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTrolamine salicylate may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Trolamine salicylate.Investigational
LepirudinTrolamine salicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTrolamine salicylate may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Trolamine salicylate.Experimental
LiraglutideTrolamine salicylate may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with ME-609.Investigational
MecaserminTrolamine salicylate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Medrysone.Approved
MelagatranTrolamine salicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Trolamine salicylate.Approved
MetforminTrolamine salicylate may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trolamine salicylate.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Trolamine salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methylprednisolone.Approved, Vet Approved
MifepristoneTrolamine salicylate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTrolamine salicylate may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Trolamine salicylate.Approved
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Trolamine salicylate.Approved
MometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone.Approved, Vet Approved
NadroparinTrolamine salicylate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTrolamine salicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Trolamine salicylate.Investigational
NateglinideTrolamine salicylate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Trolamine salicylate.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Trolamine salicylate.Approved
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Trolamine salicylate.Investigational
OtamixabanTrolamine salicylate may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateTrolamine salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineTrolamine salicylate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateTrolamine salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Trolamine salicylate.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Trolamine salicylate.Approved
PhenindioneTrolamine salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTrolamine salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Trolamine salicylate.Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Trolamine salicylate.Experimental
PioglitazoneTrolamine salicylate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Trolamine salicylate.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trolamine salicylate.Approved, Investigational
PramlintideTrolamine salicylate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Trolamine salicylate.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
Protein CTrolamine salicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanTrolamine salicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTrolamine salicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
QuinineTrolamine salicylate may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Trolamine salicylate.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Trolamine salicylate.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Trolamine salicylate.Investigational
RepaglinideTrolamine salicylate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Trolamine salicylate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trolamine salicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Reteplase.Approved, Investigational
ReviparinTrolamine salicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Trolamine salicylate.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Rimexolone.Approved
RivaroxabanTrolamine salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Rosiglitazone.Approved, Investigational
Salicylic acidSalicylic acid may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Trolamine salicylate.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Saruplase.Experimental
SaxagliptinTrolamine salicylate may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trolamine salicylate.Approved, Vet Approved
SitagliptinTrolamine salicylate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Trolamine salicylate.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Trolamine salicylate.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Streptokinase.Approved, Investigational
SulfadiazineTrolamine salicylate may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleTrolamine salicylate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleTrolamine salicylate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulodexideTrolamine salicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibTrolamine salicylate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Trolamine salicylate.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Trolamine salicylate.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Trolamine salicylate.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Trolamine salicylate.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tinzaparin.Approved
TioclomarolTrolamine salicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Trolamine salicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tixocortol.Approved, Withdrawn
TolazamideTrolamine salicylate may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideTrolamine salicylate may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Trolamine salicylate.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Trolamine salicylate.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Trolamine salicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Trolamine salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trolamine salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Trolamine salicylate.Approved, Investigational
TroxerutinTrolamine salicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Trolamine salicylate.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Trolamine salicylate.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Trolamine salicylate.Approved
WarfarinTrolamine salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTrolamine salicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Trolamine salicylate.Experimental
Food Interactions
Not Available

References

General References
  1. Rothacker DQ, Lee I, Littlejohn TW 3rd: Effectiveness of a single topical application of 10|x% trolamine salicylate cream in the symptomatic treatment of osteoarthritis. J Clin Rheumatol. 1998 Feb;4(1):6-12. [PubMed:19078236]
  2. Hill DW, Richardson JD: Effectiveness of 10% trolamine salicylate cream on muscular soreness induced by a reproducible program of weight training. J Orthop Sports Phys Ther. 1989;11(1):19-23. [PubMed:18796932]
  3. Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA: Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother. 1996 Sep;30(9):935-40. doi: 10.1177/106002809603000903. [PubMed:8876850]
  4. Sajjadi P, Khodayar MJ, Sharif Makhmalzadeh B, Rezaee S: Percutaneous absorption of salicylic Acid after administration of trolamine salicylate cream in rats with transcutol((R)) and eucalyptus oil pre-treated skin. Adv Pharm Bull. 2013;3(2):295-301. doi: 10.5681/apb.2013.048. Epub 2013 Aug 20. [PubMed:24312851]
  5. 26. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 318-322). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  6. Health Canada: Triethanolamine Salicylate (Trolamine) Label [Link]
External Links
PubChem Compound
25213
PubChem Substance
347827887
ChemSpider
23549
ChEMBL
CHEMBL2107288
Wikipedia
Trolamine_salicylate
AHFS Codes
  • 28:08.04.24 — Salicylates
MSDS
Download (47.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentMinor burns1
2Not Yet RecruitingTreatmentToothache1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentCaudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity1
4CompletedTreatmentCaudal epidural block therapy / Orthopedic Procedures / Shoulder1
Not AvailableCompletedTreatmentCerebral Palsy (CP)1
Not AvailableCompletedTreatmentErectile Dysfunction (ED)1
Not AvailableCompletedTreatmentLow Back Pain (LBP) / Pain1
Not AvailableCompletedTreatmentRecession, Gingival1
Not AvailableRecruitingBasic ScienceHeart Failure, Unspecified1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical10 g/100mL
OintmentTopical13.3 %
CreamTopical10 g/100g
LotionTopical10 %
SprayTopical100 mg/mL
SprayTopical.1 g/100mL
CreamTopical8.5 g/85g
SprayTopical10 g/100mL
LiquidTopical10 g/100g
GelTopical15 %
LotionTopical
LotionTopical10.0 %
CreamTopical
CreamTopical13.3 %
CreamTopical15 %
CreamTopical100 mg/g
PatchTopical12.5 %
GelTopical
CreamCutaneous10 g/1
CreamTopical20 %
PatchTopical
CreamTopical10 %
LotionTopical10 g/100mL
LiquidTopical100 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
PropertyValueSource
melting point (°C)50MSDS
boiling point (°C)DecomposesMSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP1.96ALOGPS
logP1.98ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity35.3 m3·mol-1ChemAxon
Polarizability12.82 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
1,2-aminoalcohols
Alternative Parents
Trialkylamines / Monocarboxylic acids and derivatives / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tertiary aliphatic amine / Tertiary amine / 1,2-aminoalcohol / Monocarboxylic acid or derivatives / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary alcohol / Organooxygen compound / Alcohol
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Topical Analgesic and Anesthetic Agents Drug Class Review [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Topical Analgesic and Anesthetic Agents Drug Class Review [Link]

Drug created on December 03, 2015 09:51 / Updated on April 17, 2018 01:11